Cullinan Therapeutics Cash Flow Statement
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
15.53+0.07 (+0.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cullinan Therapeutics free cash flow
In fiscal 2025, Cullinan Therapeutics generated -$175.8 million of operating cash flow and spent $49,000 on capital expenditures. That left free cash flow of -$175.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Cullinan Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -219.88M | -167.57M | -155.10M | 109.19M | -67.48M | -59.46M |
| Net Income growth (YoY) | — | — | -242.04% | — | — | — |
| Depreciation & Amortization | 311.00K | 306.00K | 310.00K | 93.00K | 53.00K | 62.00K |
| Stock-Based Compensation | 36.04M | 37.82M | 30.44M | 27.96M | 24.38M | 14.91M |
| Change in Working Capital | 6.06M | -3.28M | -6.11M | -1.64M | -8.10M | 5.56M |
| Operating Cash Flow | -175.75M | -145.30M | -134.28M | -126.66M | -43.43M | -29.77M |
| Capital Expenditures | -49.00K | 0 | -208.00K | -1.13M | 0 | -10.00K |
| Investing Cash Flow | 179.99M | -136.31M | 35.81M | 248.97M | -333.77M | -5.42M |
| Share Repurchases | — | — | — | — | — | -6.57M |
| Financing Cash Flow | 1.09M | 266.19M | 40.75M | -25.93M | 268.78M | 140.14M |
| Net Change in Cash | 5.33M | -15.43M | -57.72M | 96.38M | -108.42M | 104.95M |
| Free Cash Flow | -175.80M | -145.30M | -134.48M | -127.80M | -43.43M | -29.78M |
This table shows 6 annual periods of Cullinan Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CGEM's reporting calendar. What is a cash flow statement?